Why Mounjaro (Tirzepatide) Causes Vomiting: The Biology Behind It

What does the Mounjaro label say about vomiting?

Vomiting appears in the label's list of most common adverse reactions, the ones reported in at least 5% of treated patients: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain [1].

In the pooled placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 and SURPASS-5), the reported rates were 2% with placebo, 5% with 5 mg, 5% with 10 mg and 9% with 15 mg once weekly [1]. That pool covered 235 patients on placebo and 237, 240 and 241 patients on the three doses, with a mean exposure of 36.6 weeks [1].

Gastrointestinal complaints as a group were much more common than placebo: 20.4% on placebo versus 37.1% at 5 mg, 39.6% at 10 mg and 43.6% at 15 mg [1]. Treatment was stopped for gastrointestinal adverse reactions by 0.4% of placebo patients and by 3.0%, 5.4% and 6.6% of those on 5, 10 and 15 mg [1]. Severe gastrointestinal adverse reactions were reported in 1.3% (5 mg), 0.4% (10 mg) and 1.2% (15 mg) versus 0.9% on placebo [1].

What the label says about gastric emptying

The label states that Mounjaro delays gastric emptying and that this delay is largest after the first dose and diminishes over time [1]. It does not say that delayed gastric emptying is the cause of the vomiting. The label lists the delay in its drug-interaction section, where it affects the absorption of oral medicines [1].

Why vomiting clusters during dose escalation

The label instructs that the starting dosage and escalation schedule be followed to reduce the risk of gastrointestinal adverse reactions [1]. Mounjaro starts at 2.5 mg once weekly and rises in 2.5 mg steps after at least 4 weeks on the current dose if more glycemic control is needed, to a maximum of 15 mg weekly in adults and 10 mg weekly in patients aged 10 years and older [1].

In the label's words, the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1].

Do higher doses cause more vomiting?

In the pooled trials, vomiting was reported in 5% of adults at both 5 mg and 10 mg and 9% at 15 mg, against 2% on placebo [1]. A separate cardiovascular outcomes trial reported vomiting in 12% of the 6,647 adults exposed to Mounjaro, but its rate should not be compared directly with the pooled-trial rates [1].

The label cautions that adverse reaction rates from different trials cannot be directly compared, because the trials were run under different conditions [1]. In the head-to-head SURPASS-2 trial of 1,879 adults with type 2 diabetes on metformin, vomiting was reported in 6% to 10% of patients across the tirzepatide doses and in 8% of those on semaglutide 1 mg over 40 weeks [2].

A 2025 systematic review and network meta-analysis of 39 studies covering 33,354 non-diabetic adults with overweight or obesity found that liraglutide, orforglipron, semaglutide and tirzepatide were each associated with an increased risk of vomiting compared with control [3].

What the label says to watch for

Dehydration and kidney injury. The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, mostly in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. It instructs that renal function be monitored in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

Pancreatitis. The label says to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back and which may or may not be accompanied by nausea or vomiting, and to discontinue Mounjaro if pancreatitis is suspected [1].

Gastroparesis. Mounjaro is not recommended in patients with severe gastroparesis [1].